ArticleFrontiers in cellular and infection microbiology2025
Epidemiological characteristics and genomic analysis of respiratory adenovirus in Lanzhou City from 2023 to 2025.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Human adenoviruses (HAdVs) are common pathogens causing inflammation in the upper respiratory tract, lungs, conjunctiva, urinary tract, and gastrointestinal tract. They can lead to severe, even fatal infections in immunocompromised patients, representing a significant public health threat. To comprehensively assess the impact of HAdV on public health, this study investigated the epidemiological and genetic characteristics of respiratory adenoviruses in Lanzhou City from 2023 to 2025. Methods: From 2023 to 2025, 1,269 acute respiratory infection specimens were collected from sentinel hospitals in Lanzhou City. HAdV nucleic acids were detected using real-time fluorescent quantitative PCR (qPCR). A portion of HAdV-positive specimens underwent viral isolation using Hep-2 cells. Successfully isolated adenovirus strains were subjected to whole-genome sequencing. Phylogenetic trees were constructed for the HAdV whole genome, Penton base, Hexon, and Fiber genes, and protein variant sites were analyzed. Results: The overall HAdV positivity rate in acute respiratory infection specimens from Lanzhou City was 7.88% (100/1269) from 2023-2025, with a higher positivity rate observed in children aged ≤15 years. HAdV prevalence displayed seasonal variations, with significantly higher positivity rates in autumn and winter (10.83%, 73/674) compared to spring and summer (4.54%, 27/595). Whole-genome sequencing identified the predominant circulating HAdV strain in Lanzhou City during the study period as HAdV-B, all of which were HAdV-3. Phylogenetic analyses of the Penton base, Hexon, and Fiber genes revealed high genetic homology between all nine Lanzhou HAdV-B strains and the Guangzhou candidate vaccine strain (GenBank: DQ099432.4), clustering on the same branch. Furthermore, the Penton base RGD domain and Hexon antigenic epitope of the nine Lanzhou HAdV-B strains remained highly conserved compared to the Guangzhou candidate vaccine strain, showing no significant mutations. Conclusion: The prevalent HAdV strain in Lanzhou City from 2023 to 2025 was type B3. Based on these findings, it is tentatively suggested that the vaccine candidate strain from Guangzhou may provide good immune protection against these prevalent strains, though verification through clinical trials is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.